CA2546476C - Preparation pharmaceutique comprenant de la gabapentine - Google Patents

Preparation pharmaceutique comprenant de la gabapentine Download PDF

Info

Publication number
CA2546476C
CA2546476C CA2546476A CA2546476A CA2546476C CA 2546476 C CA2546476 C CA 2546476C CA 2546476 A CA2546476 A CA 2546476A CA 2546476 A CA2546476 A CA 2546476A CA 2546476 C CA2546476 C CA 2546476C
Authority
CA
Canada
Prior art keywords
gabapentin
granulate
weight
pharmaceutical composition
additives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2546476A
Other languages
English (en)
Other versions
CA2546476A1 (fr
Inventor
Luca Rampoldi
Alessandro Grassano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon SpA
Original Assignee
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon SpA filed Critical Zambon SpA
Publication of CA2546476A1 publication Critical patent/CA2546476A1/fr
Application granted granted Critical
Publication of CA2546476C publication Critical patent/CA2546476C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un granulé de gabapentine obtenu par granulation de la gabapentine avec PEG possédant un point de fusion compris entre 50 et 80 ·C et des compostions pharmaceutiques renfermant celui-ci.
CA2546476A 2003-12-09 2004-12-02 Preparation pharmaceutique comprenant de la gabapentine Expired - Lifetime CA2546476C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002399A ITMI20032399A1 (it) 2003-12-09 2003-12-09 Composizione farmaceutica contenente gabapentina.
ITMI2003A002399 2003-12-09
PCT/EP2004/053233 WO2005055993A2 (fr) 2003-12-09 2004-12-02 Preparation pharmaceutique comprenant de la gabapentine

Publications (2)

Publication Number Publication Date
CA2546476A1 CA2546476A1 (fr) 2005-06-23
CA2546476C true CA2546476C (fr) 2012-01-31

Family

ID=34674559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546476A Expired - Lifetime CA2546476C (fr) 2003-12-09 2004-12-02 Preparation pharmaceutique comprenant de la gabapentine

Country Status (21)

Country Link
US (2) US20080194687A1 (fr)
EP (1) EP1699438B1 (fr)
JP (1) JP5432433B2 (fr)
CN (1) CN100508966C (fr)
AT (1) ATE506052T1 (fr)
AU (1) AU2004296561B2 (fr)
BR (1) BRPI0417420B1 (fr)
CA (1) CA2546476C (fr)
DE (1) DE602004032382D1 (fr)
DK (1) DK1699438T3 (fr)
EA (1) EA012068B1 (fr)
ES (1) ES2363503T3 (fr)
HR (1) HRP20110346T1 (fr)
IL (1) IL175764A (fr)
IT (1) ITMI20032399A1 (fr)
NZ (1) NZ547764A (fr)
PL (1) PL1699438T3 (fr)
PT (1) PT1699438E (fr)
SI (1) SI1699438T1 (fr)
WO (1) WO2005055993A2 (fr)
ZA (1) ZA200604717B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD663617S1 (en) 2010-01-14 2012-07-17 S.C. Johnson & Son, Inc. Container with nozzle

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8607620B2 (en) * 2007-10-02 2013-12-17 Shimadzu Corporation Preparative separation/purification system
KR20190003805A (ko) * 2016-05-27 2019-01-09 한미약품 주식회사 암 세포 성장을 저해하는 아민 유도체 또는 이의 약학적으로 허용가능한 염 및 저융점을 갖는 안정화제를 포함하는 약학적 조성물
RU2731536C1 (ru) * 2019-07-30 2020-09-04 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтические композиции, содержащие фенозановую кислоту
RU2736479C1 (ru) * 2019-07-30 2020-11-17 Общество С Ограниченной Ответственностью "Консорциум-Пик" Не содержащая наполнитель фармацевтическая композиция, содержащая фенозановую кислоту

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE621097A (fr) * 1961-08-05
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
JPS58214333A (ja) * 1982-06-04 1983-12-13 Dai Ichi Seiyaku Co Ltd 粒状物
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5078990A (en) * 1990-07-13 1992-01-07 Helene Curtis, Inc. Shampoos and conditioning shampoos having increased capacity for incorporation of conditioning agents and removal of hair soil
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
EP0818990A1 (fr) * 1995-04-03 1998-01-21 Abbott Laboratories Melanges homogenes de medicaments fondant a basse temperature et d'additifs, destines a une liberation lente
CA2302275C (fr) * 1997-09-19 2009-12-08 Shire Laboratories, Inc. Granule de solution solide
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
IL125244A (en) 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
DE60211769T2 (de) * 2001-03-07 2007-05-24 Dainippon Sumitomo Pharma Co., Ltd. Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
WO2003082804A1 (fr) 2002-03-28 2003-10-09 Synthon B.V. Besylate de venlafaxine
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD663617S1 (en) 2010-01-14 2012-07-17 S.C. Johnson & Son, Inc. Container with nozzle

Also Published As

Publication number Publication date
JP5432433B2 (ja) 2014-03-05
ATE506052T1 (de) 2011-05-15
CN100508966C (zh) 2009-07-08
EA200600939A1 (ru) 2006-12-29
EP1699438B1 (fr) 2011-04-20
IL175764A (en) 2012-08-30
ITMI20032399A1 (it) 2005-06-10
EA012068B1 (ru) 2009-08-28
SI1699438T1 (sl) 2011-09-30
JP2007513920A (ja) 2007-05-31
ZA200604717B (en) 2007-03-28
DE602004032382D1 (de) 2011-06-01
IL175764A0 (en) 2008-04-13
DK1699438T3 (da) 2011-08-15
BRPI0417420B1 (pt) 2021-10-13
WO2005055993A2 (fr) 2005-06-23
AU2004296561B2 (en) 2009-02-26
CA2546476A1 (fr) 2005-06-23
ES2363503T3 (es) 2011-08-05
US8927017B2 (en) 2015-01-06
AU2004296561A1 (en) 2005-06-23
HRP20110346T1 (hr) 2011-06-30
WO2005055993A3 (fr) 2006-05-26
EP1699438A2 (fr) 2006-09-13
BRPI0417420A (pt) 2007-03-06
PT1699438E (pt) 2011-07-05
CN1889934A (zh) 2007-01-03
NZ547764A (en) 2009-09-25
US20110189272A1 (en) 2011-08-04
US20080194687A1 (en) 2008-08-14
PL1699438T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
CA2190882C (fr) Preparation de compositions de principe actif sous forme de solution solide dudit principe actif dans une matrice polymere et preparations de principe actif obtenues a l'aide dudit procede
SU1443788A3 (ru) Способ получени твердой лекарственной формы
US8927017B2 (en) Pharmaceutical preparation containing gabapentin
US20070298103A1 (en) Particulates
CN1174503A (zh) 固体活性化合物制剂
HU191558B (en) Process for production of partable pills with deferred decreasing of the reagents
CA2344372A1 (fr) Preparations et methodes de preparation pharmaceutiques a liberation controlee independante des effets alimentaires en doses unitaires multiples
JP5830412B2 (ja) 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
SI9520030A (en) Process for producing s(+)- ibuprofen-particles
JPH11501618A (ja) ヒドロキシプロピルセルロースを含有する固体の作用物質製剤
KR102388870B1 (ko) 가소제로서의 아미노 당의 용도
JPH08310969A (ja) 固形薬品組成物及びその製造方法
CZ300778B6 (cs) Zpusob výroby šumivých prípravku, obsahujících léciva a šumivé prípravky
EP3256106B1 (fr) Procédé de préparation d'une composition extrudée
JP4864369B2 (ja) チアミン類の安定化方法
EP1861075B1 (fr) Formulations granulaires revetues
JP6037824B2 (ja) エトドラク含有固形製剤
WO2004014356A1 (fr) Compositions solides comprenant de la gabapentine et presentant une stabilite amelioree
JP2018172288A (ja) 粉砕物及び錠剤の製造方法
JP2014129238A (ja) エトドラク含有固形製剤
HK1210723B (en) High dose extended-release potassium citrate wax matrix tablet
HK1210723A1 (en) High dose extended-release potassium citrate wax matrix tablet
JP2014141429A (ja) エトドラク含有粒子及びエトドラク含有固形製剤
BG99078A (en) Preparation having controllable release

Legal Events

Date Code Title Description
EEER Examination request